STAT proteins as novel targets for cancer drug discovery

Bibliography

• DARNELL JE Jr: STATs and gene regulation. Science (1997) 277:1630–1635.
   PubMed Web of Science ®Google Scholar
• SCHINDLER C, DARNELL JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Anna. Rev Biochem. (1995) 64:621–651.
   PubMed Web of Science ®Google Scholar
• BROMBERG J, DARNELL JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 19:2468–2473.
   PubMed Web of Science ®Google Scholar
• STARK GR, KERR IM, WILLIAMS BR, SILVERMAN RH, SCHREIBER RD: How cells respond to interferons. Anna. Rev Biochem. (1998) 67:227–264.
   PubMed Web of Science ®Google Scholar
• SMITHGALL TE, BRIGGS SD, SCHREINER S et at Control of myeloid differentiation and survival by stats. Oncogene (2000) 19:2612–2618.
   PubMed Web of Science ®Google Scholar
• AKIRA S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene (2000) 19:2607–2611.
   PubMed Web of Science ®Google Scholar
• HIRANO T, ISHIHARA K, HIBI M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene (2000) 19:2548–2556.
   PubMed Web of Science ®Google Scholar
• KOTENKO SV, PESTKA S: Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene (2000) 19:2557–2565.
   PubMed Web of Science ®Google Scholar
• BROMBERG J: Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. (2000) 2:86–90.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, ROSENSTIEL P, HAMPE J et al.: Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut (2002) 51:379–385.
   PubMed Web of Science ®Google Scholar
• SCHINDLER CW: Series introduction. JAK-STAT signaling in human disease. Clin. Invest. (2002) 109:1133–1137.
   PubMed Web of Science ®Google Scholar
• YU H, JOVE R: The STATS of cancer - new molecular targets come of age. Nat. Rev Cancer (2004) 4:97–105.
   PubMed Web of Science ®Google Scholar
• ••A critical analysis of the molecular basisof Stat3-mediated carcinogenesis.
   Google Scholar
• BUETTNER R, MORA LB, JOVE R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. (2002) 8:945–954.
   PubMed Web of Science ®Google Scholar
• •Examines STAT proteins as novel cancer drug targets.
   Google Scholar
• TURKSON J, JOVE R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 19:6613–6626.
   PubMed Web of Science ®Google Scholar
• •Provides a critical evaluation of Stat3 as a valid target for cancer drug discovery.
   Google Scholar
• BOWMAN T, GARCIA R, TURKSON J, JOVE R: STATs in oncogenesis. Oncogene (2000) 19:2474–2488.
   PubMed Web of Science ®Google Scholar
• •A full coverage of STAT proteins and malignant transformation.
   Google Scholar
• GARCIA R, JOVE R: Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biota-led. Sci. (1998) 5:79–85.
   Google Scholar
• YU CL, MEYER DJ, CAMPBELL GS et al.:Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 269:81–83.
   PubMed Web of Science ®Google Scholar
• ••Provides the first evidence of constitutive Stat3 in malignant transformation.
   Google Scholar
• WATSON CJ, MILLER WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. Cancer (1995) 71:840–844.
   Google Scholar
• •Earliest report of persistent STAT activity in human tumour cells.
   Google Scholar
• BESSER D, BROMBERG JF, DARNELL JE Jr, HANAFUSA H: A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Ma Cell. Biol. (1999) 19:1401–1409.
   Web of Science ®Google Scholar
• ZONG CS, ZENG L, JIANG Y, SAD OWSKI HB, WANG LH: Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol Chem. (1998) 273:28065–28072.
   PubMed Web of Science ®Google Scholar
• GARCIA R, YU CL, HUDNALL A et al.:Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ (1997) 8:1267–1276.
   PubMedGoogle Scholar
• WEN X, LIN HH, SHIH HM, KUNG HJ, ANN DK: Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. Biol. Chem. (1999) 274:38204–38210.
   Web of Science ®Google Scholar
• YU CL, JOVE R, BURAKOFF SJ: Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.j. Immunol. (1997) 159:5206–5210.
   PubMed Web of Science ®Google Scholar
• LUND TC, PRATOR PC, MEDVECZKY MM, MEDVECZKY PG: The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells. Virol (1999) 73: 1689-1694.
   Google Scholar
• MIGONE TS, LIN JX, CERESETO A et al.: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (1995) 269:79–81.
   PubMed Web of Science ®Google Scholar
• WEBER-NORDT PM, EGEN C, WEHINGER J et al: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood(1996) 88:809–816.
   PubMed Web of Science ®Google Scholar
• LUND TC, GARCIA R, MEDVECZKY MM, JOVE R, MEDVECZKY PG: Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p561ck. Virol (1997) 71:6677–6682.
   Web of Science ®Google Scholar
• NEPOMUCENO RR, SNOW AL, ROBERT BEATTY P, KRAMS SM, MARTINEZ OM: Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder. Transplantation (2002) 74:396–402.
   PubMed Web of Science ®Google Scholar
• AKIRA S: Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells (1999) 17:138–146.
   PubMed Web of Science ®Google Scholar
• TURKSON J, BOWMAN T, GARCIA R et al.: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Ma Cell. Biol. (1998) 18:2545–2552.
   Web of Science ®Google Scholar
• SHEN Y, DEVGAN G, DARNELL JE Jr, BROMBERG JF: Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Statl. Proc. Nati Acad. Sci. USA (2001) 98:1543–1548.
   PubMed Web of Science ®Google Scholar
• SONG JI, GRANDIS JR: STAT signaling in head and neck cancer. Oncogene (2000) 19:2489–2495.
   PubMed Web of Science ®Google Scholar
• COFFER PJ, KOENDERMAN L, DE GROOT RP: The role of STATs in myeloid differentiation and leukemia. Oncogene (2000) 19:2511–2522.
   PubMedGoogle Scholar
• LIN TS, MAHAJAN S, FRANK DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene (2000) 19:2496–2504.
   PubMed Web of Science ®Google Scholar
• CATLETT-FALCONE R, DALTON WS, JOVE R: STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Can: Opin. Oncol (1999) 11:490–496.
   PubMedGoogle Scholar
• SARTOR CI, DZIUBINSKI ML, YU CL, JOVE R, ETHIER SP: Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. (1997) 57:978–987.
   PubMed Web of Science ®Google Scholar
• GARCIA R, BOWMAN TL, NIU G et al.:Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 20:2499–2513.
   PubMed Web of Science ®Google Scholar
• PAGE C, HUANG M, JINX et al.: Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int. Oncol (2000) 17:23–28.
   PubMed Web of Science ®Google Scholar
• BURKE WM, JINX, LIN HJ et al: Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene (2001) 20:7925–7934.
   PubMed Web of Science ®Google Scholar
• COTARLA I, REN S, ZHANG Y et al.: Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int. .1. Cancer (2004) 108:665–671.
   Google Scholar
• REAL PJ, SIERRA A, DE JUAN A et al: Resistance to chemotherapy via Stat3-dependent overexpression of Bc1-2 in metastatic breast cancer cells. Oncogene (2002) 21:7611–7618.
   PubMed Web of Science ®Google Scholar
• LI L, SHAW PE: Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J. Biol. Chem. (2002) 277:17397–17405.
   PubMed Web of Science ®Google Scholar
• GRITSKO T, TURKSON J, KANEKO S et al.: Persistent activation of Stat3 signaling induces Survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. (2004) (In Press).
   Google Scholar
• BERCLAZ G, ALTERMATT HJ, ROHRBACH V et al.: EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int.j Oncol (2001) 19:1155–1160.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Ma Cell. Biol. (2001) 2:127–137.
   PubMed Web of Science ®Google Scholar
• CATALDO L, CHEN NY, YUAN Q et al: Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int. Oncol (2000) 17:1179–1185.
   PubMed Web of Science ®Google Scholar
• LLOVERA M, PICHARD C, BERNICHTEIN S et al.: Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene (2000) 19:4695–4705.
   PubMed Web of Science ®Google Scholar
• KAULSAY KK, MERTANI HC, TORNELL J et al: Autocrine stimulation of the human mammary carcinoma cell proliferation by human growth hormone. Exp. Cell Res. (1999) 250:35–50.
   PubMed Web of Science ®Google Scholar
• RICHER JK, LANGE CA, MANNING NG et al.: Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. Biol. Chem. (1998) 273:31317–31326.
   Google Scholar
• GRANT SL, HAMMACHER A, DOUGLAS AM et al.: An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene (2002) 21:460–474.
   PubMed Web of Science ®Google Scholar
• BADACHE A, HYNES NE: Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res. (2001) 61:383–391.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, DRENNING SD, ZENG Q et al.: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Nati Acad. Sci. USA (2000) 97:4227–4232.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, DRENNING SD, CHAKRABORTY A et al.: Requirement of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth M vitro. Clin. Invest. (1998) 102:1385–1392.
   Google Scholar
• LEONG PL, XIS, DRENNING SD et al.: Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene (2002) 21:2846–2853.
   PubMed Web of Science ®Google Scholar
• NAGPAL JK, MISHRA R, DAS BR: Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer (2002) 94:2393–2400.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, ZENG Q, DRENNING SD: Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope (2000) 110:868–874.
   PubMed Web of Science ®Google Scholar
• LEONG PL, ANDREWS GA, JOHNSON DE et al.: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Nati Acad. Sci USA (2003) 100:4138–4143.
   PubMed Web of Science ®Google Scholar
• KIJIMA T, NIWA H, STEINMAN RA et al.: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth M vivo. Cell Growth Differ. (2002) 13:355–362.
   PubMedGoogle Scholar
• MASUDA M, SUZUI M, YASUMATU R et al.: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin dl overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. (2002) 62:3351–3355.
   PubMed Web of Science ®Google Scholar
• XIS, ZHANG Q, DYER KF et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. (2003) 278:31574–31583.
   PubMed Web of Science ®Google Scholar
• SRIURANPONG V, PARK JI, AMORNPHIMOLTHAM P et al.: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. (2003) 63:2948–2956.
   PubMed Web of Science ®Google Scholar
• NIU G, HELLER R, CATLETT-FALCONE R et al.: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. (1999) 59:5059–5063.
   PubMed Web of Science ®Google Scholar
• ••Provides the first proof-of-principle for the therapeutic potential of inhibition of constitutive Stat3 in tumours.
   Google Scholar
• NIU G, SHAIN K, HUANG M et al.: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. (2001) 61:3276–3280.
   PubMed Web of Science ®Google Scholar
• NIU G, BOWMAN T, HUANG M et al.: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 21:7001–7010.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, FARKAS DL, CHAKRABORTY A et al.: Systemic interferon-a (IFN-a) treatment leads to stat3 inactivation in melanoma precursor lesions. Mol. Med. (1999) 5:11–20.
   PubMed Web of Science ®Google Scholar
• NIU G, WRIGHT KL, HUANG M et al.: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 21: 2000-2008.
   Google Scholar
• KRASIUNIKOV M, SHATSKAYA V: Signal transducer and activator of transcription-3 and phosphatidylinosito1-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J. Steroid Biochem. Mol. Biol. (2002) 82:369–376.
   PubMed Web of Science ®Google Scholar
• WELLBROCK C, GEISSINGER E, GOMEZ A et al.: Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. Oncogene (1998) 16:3047–3056.
   PubMed Web of Science ®Google Scholar
• MORCINEK JC, WEISSER C, GEISSINGER E, SCHARTL M, WELLBROCK C: Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. Oncogene (2002) 21: 1668-1678.
   Google Scholar
• NI Z, LOU W, LEMAN ES, GAO AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. (2000) 60:1225–1228.
   PubMed Web of Science ®Google Scholar
• GAO B, SHEN X, KUNOS G et al.: Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. (2001) 488:179–184.
   PubMed Web of Science ®Google Scholar
• MORA LB, BUETTNER R, SEIGNE J et al.: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. (2002) 62:6659–6666.
   PubMed Web of Science ®Google Scholar
• DHIR R, NI Z, LOU W et al.: Stat3 activation in prostatic carcinomas. Prostate (2002) 51:241–246.
   PubMed Web of Science ®Google Scholar
• CAMPBELL CL, JIANG Z, SAVARESE DM, SAVARESE TM: Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am. Pathol. (2001) 158:25–32.
   PubMed Web of Science ®Google Scholar
• BARTON BE, MURPHY TF, ADEM P et al.: IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer (2001) 1:19.
   PubMed Web of Science ®Google Scholar
• BARTON BE, KARRAS JG, MURPHY TF, BARTON A, HUANG HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. (2004) 3:11–20.
   PubMed Web of Science ®Google Scholar
• NI Z, LOU W, LEE SO et al.: Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. Urol. (2002) 167:1859–1862.
   Web of Science ®Google Scholar
• SMITH PC, HOBISCH A, LIN DL, CULIG Z, KELLER ET: Interleuldn-6 and prostate cancer progression. Cytokine Growth Factor Rev (2001) 12:33–40.
   PubMed Web of Science ®Google Scholar
• LEE SO, LOU W HOU M et al: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Cl/n. Cancer Res. (2003) 9:370–376.
   PubMed Web of Science ®Google Scholar
• LOU W, NI Z, DYER K, TWEARDY DJ, GAO AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate (2000) 42:239–242.
   PubMed Web of Science ®Google Scholar
• SEKHARAM M, TURKSON J, JOVE R, CALVIN D: Radiosensitization of prostate cancer cell line, DU145 by novel Stat3 inhibitor, CPA-7. I. Exp. Ther. Oncol (2004) (In press).
   Google Scholar
• CATTANEO E, MAGRASSI L, DE-FRAJA C et al.: Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res. (1998) 18:2381–2387.
   PubMed Web of Science ®Google Scholar
• SCHAEFER LK, REN Z, FULLER GN, SCHAEFER TS: Constitutive activation of Stat3a in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene (2002) 21:2058–2065.
   PubMed Web of Science ®Google Scholar
• RAHAMAN SO, HARBOR PC, CHERNOVA O et al.: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 21:8404–8413.
   PubMed Web of Science ®Google Scholar
• KONNIKOVA L, KOTECKI M, KRUGER MM, COCHRAN BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 3:23.
   PubMed Web of Science ®Google Scholar
• PAILLAUD E, COSTA S, FAGES C et al.: Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor. Neurosci. Res. (2002) 67:670–679.
   Web of Science ®Google Scholar
• REBBAA A, CHOU PM, MIRKIN BL: Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Ma Med. (2001) 7:393–400.
   PubMed Web of Science ®Google Scholar
• SCHAEFER LK, MENTER DG, SCHAEFER TS: Activation of Stat3 and Statl DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell. Signal (2000) 12:143–151.
   PubMed Web of Science ®Google Scholar
• LI B, CHANG CM, YUAN M, MCKENNA WG, SHU HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. (2003) 63:7443–7450.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, NOWAK I, VONDERHEID EC et al: Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA (1996) 93:9148–9153.
   PubMed Web of Science ®Google Scholar
• CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10:105–115.
   PubMed Web of Science ®Google Scholar
• ••Provides the first evidence for constitutiveactivation of Stat3 in multiple myeloma and identifies Bd-xL as a Stat3 downstream target.
   Google Scholar
• ERIKSEN KW, KALTOFT K, MIKKELSEN G et al.: Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 15:787–793.
   PubMed Web of Science ®Google Scholar
• EPLING-BURNETTE PK, LUI JH, CATLETTE-FALC ONER et al.: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. Clin. Invest. (2001) 107:351–362.
   Google Scholar
• KIRITO K, NAGASHIMA T, OZAWA K, KOMATSU N: Constitutive activation of Statl and Stat3 in primary erythroleukemia cells. Int.j Hematol (2002) 75:51–54.
   PubMed Web of Science ®Google Scholar
• SPIEKERMANN K, BIETHAHN S, WILDE S, HIDDEMANN W, ALVES F: Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur. Haematol (2001) 67:63–71.
   PubMed Web of Science ®Google Scholar
• QUINTANILLA-MARTINEZ L, KREMER M, SPECHT K et al.: Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am. Pathol (2003) 162:1449–1461.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, RAGHUNATH PN, XUE L et al.: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Inlinunol. (2002) 168:466–474.
   Google Scholar
• HOD GE DR, XIAO W, WANG LH, LID,FARRAR WL: Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol. Ther. (2004) 3:2.
   Web of Science ®Google Scholar
• BURGER R, BAKKER F, GUENTHER Aet al.: Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br. Haematol (2003) 123:869–878.
   Google Scholar
• ALAS S, BONAVIDA B: Ritwdmab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine/paracrine loop and results in down-regulation of Bc1-2 and sensitization to cytotoxic drugs. Cancer Res. (2001) 61:5137–5144.
   PubMed Web of Science ®Google Scholar
• GALM O, YOSHIKAWA H, ESTELLER M, OSIEKA R, HERMAN JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood(2003) 101:2784–2788.
   PubMed Web of Science ®Google Scholar
• CHEN CY, TSAY W, TANG JL et al.: SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer (2003) 37:300–305.
   PubMed Web of Science ®Google Scholar
• CHENG J, ZHANG D, ZHOU C, MARASCO WA: Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells. Leak. Res. (2004) 28:71–82.
   PubMed Web of Science ®Google Scholar
• ZAMO A, CHIARLE R, PIVA R et al.: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 21:1038–1047.
   PubMed Web of Science ®Google Scholar
• SPIEKERMANN K, PAU M, SCHWAB R et al.: Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp. Hematol (2002) 30:262–271.
   PubMedGoogle Scholar
• HORITA M, ANDREU EJ, BENITO A et al.: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bc1-xL. I Exp. Med. (2000) 191:977–984.
   PubMed Web of Science ®Google Scholar
• HUANG M, DORSEY JF, EPLING-BURNETTE PK et al.: Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 21:8804–8816.
   PubMed Web of Science ®Google Scholar
• GESBERT F, GRIFFIN JD: Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood (2000) 96:2269–2276.
   PubMed Web of Science ®Google Scholar
• Ha NIELSEN M, KAESTEL CG, ERIKSEN KW et al.: Inhibition of constitutively activated Stat3 correlates with altered Bc1-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 13:735–738.
   PubMed Web of Science ®Google Scholar
• PUTHIER D, BATAILLE R, AMIOT M: IL-6 up-regulates mc1-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. EuL I Immunol. (1999) 29:3945–3950.
   PubMed Web of Science ®Google Scholar
• PUTHIER D, THABARD W, RAPP M et al.: Interferon a extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br. Haematol. (2001) 112:358–363.
   PubMed Web of Science ®Google Scholar
• PANER GP, SILBERMAN S, HARTMAN G et al.: Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res. (2003) 23:2253–2260.
   PubMed Web of Science ®Google Scholar
• HORIGUCHI A, OYA M, MARUMO K, MURAI M: STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P Kidney Int. (2002) 61:926-938.
   Google Scholar
• LEU CM, WONG FH, CHANG C, HUANG SF, HU CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene (2003) 22:7809–7818.
   PubMed Web of Science ®Google Scholar
• WEI D, LE X, ZHENG L et al.: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 22:319–329.
   PubMed Web of Science ®Google Scholar
• DEARMOND D, BRATTAIN MG, JESSUP JM et al.: Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene (2003) 22:7781–7795.
   PubMed Web of Science ®Google Scholar
• WEI LH, KUO ML, CHEN CA et al.: The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mc-1 through a P13-K/Akt pathway. Oncogene (2001) 20:5799–5809.
   PubMed Web of Science ®Google Scholar
• HUANG M, PAGE C, REYNOLDS RK, LIN J: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol. Oncol. (2000) 79:67–73.
   PubMed Web of Science ®Google Scholar
• KANAI M, KONDA Y, NAKAJIMA T et al.: Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene (2003) 22:548–554.
   PubMed Web of Science ®Google Scholar
• COLLUM RG, BRUTSAERT S, LEE G, SCHINDLER C: A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc. Nati Acad. ScL USA (2000) 97:10120–10125.
   PubMed Web of Science ®Google Scholar
• CALO V, MIGLIAVACCA M, BAZAN V et al.: STAT proteins: from normal control of cellular events to tumorigenesis. Physiol. (2003) 197:157–168.
   Web of Science ®Google Scholar
• KILE BT, NICOLA NA, ALEXANDER WS: Negative regulators of cytokine signaling. Int. Hematol. (2001) 73:292–298.
   PubMed Web of Science ®Google Scholar
• SHUAI K: Modulation of STAT signaling by STAT-interacting proteins. Oncogene (2000) 21:2638–2644.
   Google Scholar
• YASUKAWA H, SASAKI A, YOSHIMURA A: Negative regulation of cytokine signaling pathways. Annu. Rev Immunol. (2000) 18:143–164.
   PubMed Web of Science ®Google Scholar
• CHEN XP, LOSMAN JA, ROTHMAN P: SOCS proteins, regulators of intracellular signaling. Immunity (2000) 13:287–290.
   PubMed Web of Science ®Google Scholar
• SHUAI K: The STAT family of proteins in cytokine signaling. Frog. Biophys. Mol. Biol. (1999) 71:405–422.
   PubMed Web of Science ®Google Scholar
• NAGAI H, KIM YS, KONISHI N et al.: Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett. (2002) 186:59–65.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA H, MATSUBARA K, QIAN GS et al.:SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. (2001) 28:29–35.
   PubMed Web of Science ®Google Scholar
• SINIBALDI N, WHARTON W, TURKSON J et al.: Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene (2000) 19:5419–5427.
   PubMed Web of Science ®Google Scholar
• BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G et al.: Stat3 as an oncogene. Cell (1999) 98:295–303.
   PubMed Web of Science ®Google Scholar
• ••Definitive proof for Stat3 as an oncogene.
   Google Scholar
• AOKI Y, FELDMAN GM, TOSATO G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood (2003) 101:1535–1542.
   PubMed Web of Science ®Google Scholar
• WANG T, NIU G, KORTYLEWSKI M et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. (2004) 10:48–54.
   PubMed Web of Science ®Google Scholar
• •First evidence for tumour immune evasion by constitutively active Stat3.
   Google Scholar
• OSHIRO MM, LANDOWSKI TH, CATLETT-FALCONE R et al.: Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin. Cancer Res. (2001) 7:4262–4271.
   PubMed Web of Science ®Google Scholar
• BLASKOVICH MA, SUN J, CANTOR A et al.: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. (2003) 63:1270–1279.
   PubMed Web of Science ®Google Scholar
• SEBTI S: New drug targets and therapies for cancer. Oncol. Rev (2000) 19:6549–6692.
   Google Scholar
• DANCEY JE: Recent advances of molecular targeted agents: opportunities for imaging. Cancer Biol. The]: (2003) 2:601–609.
   PubMed Web of Science ®Google Scholar
• TURKSON J, KIM JS, ZHANG S et al.: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. (2004) 3:261–269.
   PubMed Web of Science ®Google Scholar
• ••Provides evidence for peptidomimeticsas novel small-molecule inhibitors of Stat3 signalling with biological activity.
   Google Scholar
• TURKSON J, ZHANG S, PALMER J et al.: Inhibition of constitutive Stat3 activation by novel platinum complexes with potent anti-tumor activity. Mol. Cancer Ther. (2004) (In press). Expert Op/n. Ther. Targets (2004) 8(5)
   Google Scholar
• TURKSON J, RYAN D, KIM JS et al: Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. Biol. Chem. (2001) 276:45443–45455.
   Web of Science ®Google Scholar
• ••First evidence for a structure-basedapproach to the design of small-molecule inhibitors of Stat3 activation, and proof-of-concept for inhibition of Stat3 by peptide derivatives.
   Google Scholar
• SHUAI K, STARK GR, KERR IM, DARNELL JE Jr: A single phosphotyrosine residue of Stat91 required for gene activation by interferon-y. Science (1993) 261: 1744-1746.
   Google Scholar
• SHUAI K, HORVATH CM, HUANG LH et al.: Interferon activation of the transcription factor Stat91 involves dimerization through 5H2-phosphotyrosyl peptide interactions. Cell (1994) 76:821–828.
   PubMed Web of Science ®Google Scholar
• SCHAEFER TS, SANDERS LK, PARK OK, NATHANS D: Functional differences between Stat3a and Stat3. MM. Cell. Biol. (1997) 17:5307–5316.
   Web of Science ®Google Scholar
• SASSE J, HEMMANN U, SCHWARTZ C et al.: Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. MM. Cell. Biol. (1997) 17:4677–4686.
   Web of Science ®Google Scholar
• BECKER S, GRONER B, MULLER CW: Three-dimensional structure of the Stat33 homodimer bound to DNA. Nature (1998) 394:145–151.
   PubMed Web of Science ®Google Scholar
• REN Z, CABELL LA, SCHAEFER TS, MCMURRAY JS: Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. (2003) 13:633–636.
   PubMed Web of Science ®Google Scholar
• NAGEL-WOLFRUM K, BUERGER C, WITTIG I et al: The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Ma Cancer Res. (2004) 2:170–182.
   PubMed Web of Science ®Google Scholar
• JING N, LI Y, XU X et al.: Targeting Stat3 with G-quartet ofigodeoxynucleotides in human cancer cells. DNA Cell Biol. (2003) 22:685–696.
   PubMed Web of Science ®Google Scholar
• BERG T, COHEN SB, DESHARNAIS J et al.: Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA (2002) 99:3830–3835.
   PubMed Web of Science ®Google Scholar
• •One of the first examples of disruption of transcription factor dirnerisation by a small-molecule inhibitor.
   Google Scholar